CoChat

Albiglutide: First Global Approval

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Albiglutide (Eperzan® [EU]; Tanzeum™ [US]), a glucagon-like peptide 1 receptor agonist, has been developed by GlaxoSmithKline for the treatment of type 2 diabetes mellitus (T2DM). Albiglutide has received its first global approval in this indication in the EU, for use in combination with other antihyperglycaemic agents, including basal insulin, when these drugs and diet and exercise do not provide adequate glycaemic control, and as monotherapy in patients unable to take metformin due to contraindications or intolerance when diet and exercise alone do not provide adequate glycaemic control. Albiglutide has subsequently been approved for the second-line or later treatment of T2DM as an adjunct to diet and exercise in the US. This article summarizes the milestones in the development of albiglutide leading to this first approval for the treatment of T2DM.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-014-0228-2

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Research works printed but not linked: 6

  1. Bush MA, Smith C, Watanalumlerd P, et al. Population pharmacokinetic (PK) analysis of albiglutide in a phase iib study in Japanese patients with type 2 diabetes. Diabetes. 2012;61:A261–2.
  2. Fonseca VL, Ahren B, Chow F, et al. Once weekly GLP-1 receptor agonist albiglutide vs prandial lispro added to basal glargine in type 2 diabetes: similar glycaemic control with weight loss and less hypoglycaemia. Diabetologia. 2012;55:S241.
  3. Pratley RE, Barnett A, Feinglos MM, et al. Efficacy and safety of once-weekly (QW) albiglutide vs. once-daily (QD) liraglutide in type 2 diabetes (T2D) inadequately controlled on oral agents: Harmony 7 trial. Diabetes. 2012;61:A240–1.
  4. Martin AA, Johnson SL, Ye J, et al. Improved treatment satisfaction with weekly abiglutide vs. Thrice daily prandial insulin added to insulin glargine in type 2 diabetes. Diabetes. 2013;62:A659.
  5. Martin AA, Johnson SL, Ye J, et al. Treatment satisfaction with albiglutide and liraglutide in patients with type 2 diabetes uncontrolled with oral therapy. Diabetes. 2013;62:A259–60.
  6. Seino Y, Inagaki N, Miyahara H, et al. Albiglutide significantly lowers glycemia in japanese patients with type 2 diabetes (T2D). Diabetes. 2012;61:A248.

Cited by

See all 49

Metadata

Authors
Poole, R. M., & Nowlan, M. L.
Corresponding author
Nowlan, Mary L.
Venue
Drugs
Published
2014-05-27
Volume
74
Issue
8
Pages
929-938
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W2084245396
Cited by
49
References
18
Citations by year
2026: 6 · 2025: 7 · 2024: 7 · 2023: 1 · 2022: 7 · 2021: 2 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 5 · 2015: 4 · 2014: 5
FWCI
4.02
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
albiglutide, type 2 diabetes, GLP-1 receptor agonists, drug approval, antidiabetic drugs, metformin intolerance, glycemic control, drug development milestones
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Drug Approval, Receptors, Glucagon, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Albiglutide: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-014-0228-2
The paper
Poole, R. M., & Nowlan, M. L. (2014). Albiglutide: First Global Approval. Drugs. https://doi.org/10.1007/s40265-014-0228-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.